We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The impact of different (rheumatoid) arthritis phenotypes on patients' lives.
- Authors
Luurssen-Masurel, Nathalie; Weel, Angelique Elisabeth Adriana Maria; Hazes, Johanna Maria Wilhelmina; Jong, Pascal Hendrik Pieter de; investigators, the tREACH group
- Abstract
Objectives To compare patient-reported outcome (PRO) domains between three arthritis phenotypes [undifferentiated arthritis (UA), autoantibody-negative RA (RA−) and autoantibody-positive RA (RA+)] at diagnosis, after 2 years and over time. Methods All UA (n = 130), RA− (n = 176) and RA+ (n = 331) patients from the tREACH trial, a stratified single-blinded trial with a treat-to-target approach, were used. PRO comparisons between phenotypes at baseline and after 2 years were performed with analysis of variance, while a linear mixed model compared them over time. Effect sizes were weighted against the minimal clinically important differences (MCIDs) for each PRO. Results RA− patients had a higher disease burden compared with RA+ and UA. At baseline and after 2 years, RA− patients had more functional impairment and a poorer Physical Component Summary (PCS) compared with the other phenotypes, while they only scored worse for general health and morning stiffness duration at baseline. The MCIDs were exceeded at baseline, except for functional ability between RA+ and UA, while after 2 years only the MCID of the PCS was exceeded by RA− compared with UA and RA. After 2 years the PROs of all phenotypes improved, but PROs measuring functioning were still worse compared with the general population, even when patients had low disease activity. Conclusion RA− patients had the highest disease burden of all phenotypes. Although most patients have low disease activity after treatment, all clinical phenotypes still have a similar significant impact on patients' lives, which is mainly physical. Therefore it is important to assess and address PROs in daily practice because of persistent disease burden despite low disease activity. Trial registration ISRCTN26791028.
- Subjects
RHEUMATOID arthritis diagnosis; AUTOANTIBODIES; FUNCTIONAL status; ACTIVITIES of daily living; HEALTH outcome assessment; RANDOMIZED controlled trials; COMPARATIVE studies; TREATMENT effectiveness; QUALITY of life; DISEASE duration; ECONOMIC aspects of diseases; STATISTICAL sampling; PHENOTYPES
- Publication
Rheumatology, 2021, Vol 60, Issue 8, p3716
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/keaa845